Program
IBI3042
A development code. Also written as “Investigational Drug: IBI3042”.
Its studies are mostly in Obesity, led by Innovent Biologics.
Furthest: phase 1, since Aug 20, 20262 company-led studies, 2 open or runningNext primary completion: Feb 3, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 22 open or running | phase 1since Aug 20, 2026 | Aug 20, 2026 | Feb 3, 2027phase 1 · NCT07842393 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2026First study: phase 1 study in OverweightFirst studyNCT07793019 · 104 planned · China
- Sep 16, 2026Phase 1 study in Healthy Volunteers (HV)NCT07842393 · 32 planned · United States
Ahead
- Feb 3, 2027Primary completion: phase 1 study in Healthy Volunteers (HV)NCT07842393
- Sep 6, 2027Primary completion: phase 1 study in OverweightNCT07793019
TargetBeta
GLP1R →read by rule
“The goal of this study is to learn about the safety and tolerability of IBI3042, an investigational oral drug that activates the glucagon-like peptide-1 (GLP-1) receptor.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07842393Healthy Volunteers (HV) · United States | 1 | Not yet recruiting | Feb 3, 2027 | 32 |
| NCT07793019Overweight · China | 1 | Recruiting | Sep 6, 2027 | 104 |
How it is read
Names in the registry
- “Investigational Drug: IBI3042”, 1 entry
- “IBI3042”, 1 entry
Codes read as this program: IBI3042.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.